Literature DB >> 29752210

Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States.

Anuhya Kommalapati1, Sri Harsha Tella2, Apar Kishore Ganti3, James O Armitage4.   

Abstract

BACKGROUND: Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer (NK)/T-cell neoplasms in the United States. PATIENTS AND METHODS: We performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The Kaplan-Meier method was used to estimate the overall survival difference among the subgroups. Multivariate analyses were used to determine the factors affecting survival.
RESULTS: For the 797 patients with NK/T-cell lymphoma, nasal type, the median age at diagnosis was 53 years, and males tended to be younger at diagnosis (P < .0001). The incidence of the disease increased from 0.4 in 2001 to 0.8 in 2014 per 1,000,000 individuals. The incidence was significantly greater in Hispanic patients compared with that in non-Hispanic patients (rate ratio, 3.03; P = .0001). The median overall survival was 20 months (range, 2-73 months) and varied significantly according to the primary site (P < .0001) and the disease stage at diagnosis (P < .0001). NK/T-cell lymphoma patients had an increased risk of acute myeloid leukemia (standardized incidence ratio, 18.77; 95% confidence interval, 2.27-67.81). For the 105 NK/T-cell leukemia patients, the median age at diagnosis was 58 years (range, 4-95 years). The overall incidence of the disease was 0.09 per 1,000,000 individuals and was significantly greater in males (rate ratio, 0.41; P < .0001). Unlike NK/T-cell lymphoma, no racial disparities were found in the incidence. The median overall survival was 17 months (range, 0-36 months).
CONCLUSION: The incidence of NK/T-cell lymphoma, nasal type, in the United States has at least doubled in the past decade, with the greatest predilection among Hispanics. Patients with NK/T-cell lymphoma might have an increased risk of the subsequent development of acute myeloid leukemia.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; NK/T-cell leukemia; NK/T-cell lymphoma; Overall survival; SEER

Mesh:

Year:  2018        PMID: 29752210     DOI: 10.1016/j.clml.2018.04.009

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  5 in total

1.  Management of NK/T-Cell Lymphoma, Nasal Type.

Authors:  Pamela B Allen; Mary Jo Lechowicz
Journal:  J Oncol Pract       Date:  2019-10       Impact factor: 3.840

2.  Extranodal natural killer/T-cell lymphoma nasal type.

Authors:  Benjamin S Daines; Rahul M Varman; Tam Q Nguyen
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-05-16

3.  Sinonasal relapses of a primary isolated extranodal NK/T-cell lymphoma of the testis.

Authors:  Bassel Hallak; Anne Cairoli; Salim Bouayed; Grégoire Berthod
Journal:  BMJ Case Rep       Date:  2019-08-13

4.  Recurrent Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma with Meningeal Involvement.

Authors:  Sylvester Homsy; Ralph Kamel; Mark Raden; Yevgeniy Skaradinskiy
Journal:  Case Rep Hematol       Date:  2021-07-24

5.  Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG).

Authors:  Wei-Xin Liu; Mei Shi; Hang Su; Ying Wang; Xia He; Li-Ming Xu; Zhi-Yong Yuan; Li-Ling Zhang; Gang Wu; Bao-Lin Qu; Li-Ting Qian; Xiao-Rong Hou; Fu-Quan Zhang; Yu-Jing Zhang; Yuan Zhu; Jian-Zhong Cao; Sheng-Min Lan; Jun-Xin Wu; Tao Wu; Su-Yu Zhu; Shu-Nan Qi; Yong Yang; Bo Chen; Ye-Xiong Li
Journal:  Aging (Albany NY)       Date:  2019-10-06       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.